SK Capital’s investment will serve as a catalyst for a new strategic direction as the Company seeks to deepen and expand its presence in fine chemistries for the global life science market.
We are launching the five new products in the new manufacturing facility and they're all pharmaceuticals and this should lead to an increase in pharma numbers.
Manish led SeQuent since 2014 and played a major role in transforming the company
The appointments will add to the well-diversified experience that currently exists on the PPL board.
The company has a total sales of Rs. 25.8 crore during FY 21-22 and Rs. 26.4 crore during FY 20-21.
Multiples is the first private equity (PE) investor in the company
According to the brokerage, as the pandemic has receded, the past exceptional growth in acute therapies may not be repeated (stellar double-digit growth for anti-infectives coming down)
A growing portfolio of chemicals is part of a larger quality management system that sets new standards in bioprocessing
Large players are adequately capitalised to make bigger investments to adjust for the ongoing fundamental shift in market opportunities
He will continue to lead business in LATAM and Asia regions in this new role
Subscribe To Our Newsletter & Stay Updated
